Health Care Industry
Industry: Email Alert RSS FeedHow umbilical cord stem cells are helping life imitate myth
Townsend Letter for Doctors and Patients, Dec, 2005 by Anthony G. Payne
They are safe, because there is no graft versus host or rejection issues (as is the case with whole cord blood).
No immunosuppressant drugs are needed.
Best responders (so far): Cerebral palsy, traumatic brain injury, diabetic retinopathy and neuropathy, early stage progressive and secondary progressive multiple sclerosis, and Lou Gehrig's disease.
Poor responders (so far): Advanced multiple sclerosis and Lou Gehrig's disease, advanced COPD (emphysema), Charco Marie Tooth disease and diabetes type I (Insulin production and utilization).
Diseases for which insufficient patient response data exists yet to determine efficacy of hUCSCT: Parkinson's disease, Alzheimer's disease, retinitis pigmentosa, and a host of other eye, circulatory, neurologic and other diseases and conditions.
RELATED ARTICLE: SRI: The Little Nonprofit Institute That Could
* Founded 2003. Staff of 2, now 7
* 12,000+ vol. medical & scientific library
* Developed USPTO Patent Pending protocols for pre- and post-hUCSC therapy
* Has accrued data and case history documentation on over 125 patients treated with hUCSCs (in Mexico)
* Asked by the White House to provide input on human umbilical cord stem cells to President Bush (October 2004)
* Is providing technical support & data analysis to those involved in doing the world's first use of gene transvected hUCSCs to treat the terminal neurologic condition Metachromatic Leukodystrophy
COPYRIGHT 2005 The Townsend Letter Group
COPYRIGHT 2006 Gale Group